Form 4: Evolent Health CFO John Paul Johnson Sells Shares Under 10b5-1 Trading Plan

Evolent Health's CFO, John Paul Johnson, sold 44,693 shares of Class A Common Stock at a weighted average price of $30.00 on August 22, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On August 22, 2024, John Paul Johnson, the Chief Financial Officer of Evolent Health, Inc., sold 44,693 shares of Class A Common Stock.
• The sale was executed at a weighted average price of $30.00 per share.
• The transactions were carried out under a Rule 10b5-1 trading plan adopted on March 1, 2024.
• Following the transaction, Johnson directly owns 171,207 shares of Evolent Health, Inc.
• The price per share ranged from $30.00 to $30.01.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is part of a pre-planned trading strategy (Rule 10b5-1) and doesn't necessarily reflect a change in the executive's confidence in the company.

Industry Context

Sales by company insiders are routinely monitored by investors. A pre-planned sale under a 10b5-1 plan is generally viewed as less impactful than discretionary sales, as it indicates a pre-arranged strategy rather than a reaction to current market conditions.

Comparison to Industry Standards

• Executive stock sales are a common occurrence in publicly traded companies.
• The use of 10b5-1 trading plans is a standard practice to avoid accusations of insider trading.
• Comparable companies like Molina Healthcare and UnitedHealth Group also see regular insider trading activity, often under similar 10b5-1 plans.

Stakeholder Impact

• The sale of shares by a high-ranking executive could cause short-term uncertainty among shareholders.
• However, the existence of a 10b5-1 trading plan mitigates concerns about insider trading and suggests a pre-arranged strategy.

Key Dates